Search Results

Now showing 1 - 6 of 6

Some of the metrics are blocked by your
consent settings
Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non–muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current European Association of Urology and American Urological Association Stratification Schemes
(Elsevier BV, 2025-10)
Sam S. Chang
;
Bryn Launer
;
Vikram Narayan
;
Dattatraya Patil
;
Michael A. O’Donnell
1Scopus© Citations 10
Some of the metrics are blocked by your
consent settings
Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection
(2024)
Roger Li
;
Patrick J. Hensley
;
Shilpa Gupta
;
Hikmat Al-Ahmadie
;
Marko Babjuk
Scopus© Citations 15 4
Some of the metrics are blocked by your
consent settings
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile
(2023)
Valentina Grajales
;
Roberto Contieri
;
Wei Shen Tan
;
Marta Flores
;
Marcela Schultz
<jats:p>BACKGROUND: Adjuvant bacillus Calmette-Guérin (BCG) is recommended for high-risk (HR) non-muscle invasive bladder cancer (NMIBC), but BCG shortages have led to exploration of reduced-dose regimens and shortened maintenance durations out of necessity, with limited data on treatment efficacy in Latin America. OBJECTIVE: Oncological outcomes of HR-NMIBC patients treated with reduced (RD,1/4th dose) vs full dose (FD) BCG instillations of Danish Strain 1331 BCG. METHODS: We performed a retrospective study of HR-NMIBC patients treated with BCG between 2003 and 2022 at our center in Santiago Chile. We stratified patients according to either RD (1/4th dose) or FD BCG. Univariate and multivariable Cox regression models were used to predict recurrence. Kaplan-Meier method was used to calculate survival estimates. RESULTS: Of a total of 200 patients, 116 (58%) had RD and 84 (42%) FD BCG. Median follow-up was 57 months (IQR: 29–100). Patients who received FD BCG had a lower risk of recurrence (HR: 0.41, 95% CI 0.22–0.74) and high-grade (HG)-recurrence (HR: 0.30, 95% CI 0.15–0.61; p = 0.001). More patients in the RD vs FD group progressed to MIBC (10/84 vs 2/116; p = 0.18). Additionally, patients were less likely to stop BCG treatment in the RD group compared to the FD group due to toxicity (5% vs 11%, p = 0.14). CONCLUSIONS: A 1/4th dose of Danish Strain 1331 BCG treatment was associated with worse recurrence free rate and HG-recurrence rate in our cohort. Patients with RD had lower discontinuation treatment rates due to a reduced toxicity profile. These findings would suggest that RD BCG would compromise oncological outcomes in HR-NMIBC patients.</jats:p>
7Scopus© Citations 2
Some of the metrics are blocked by your
consent settings
Patient and Carer Experiences with Bladder Cancer: Results from a Global Survey in 45 Countries
(2023)
Lydia E. Makaroff
;
Alex Filicevas
;
Shannon Boldon
;
Patrick Hensley
;
Peter C. Black
7Scopus© Citations 8
Some of the metrics are blocked by your
consent settings
What Is the Significance of Variant Histology in Urothelial Carcinoma?
(2020)
Niyati Lobo
;
Shahrokh F. Shariat
;
Charles Chuanhai Guo
;
FERNANDEZ ARANCIBIA, MARIO
;
Wassim Kassouf
1Scopus© Citations 181 4
Some of the metrics are blocked by your
consent settings
Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD–SIU joint consultation on bladder cancer
(2019)
FERNANDEZ ARANCIBIA, MARIO
;
Maurizio Brausi
;
Peter E. Clark
;
Michael S. Cookson
;
H. Barton Grossman
Scopus© Citations 50 1

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results